CatherineCCoombsMD

PubMed

• 344 citations
  Cancer therapy shapes the fitness landscape of clonal hematopoiesis
  Kelly L. Bolton, Ryan Ptashkin, Teng Gao, Lior Z. Braunstein, Sean M. Devlin
  Nature Genetics. 2020-10-26
• 6 citations
  Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
  Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan
  Clinical Lymphoma, Myeloma & Leukemia. 2023-07-01
• 499 citations
  Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.
  Catherine C. Coombs, Ahmet Zehir, Sean M. Devlin, Ashwin Kishtagari, Aijazuddin Syed
  Cell Stem Cell. 2017-09-07

Abstracts/Posters

• Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all